Citations

Clear

1792 citation(s) found for "Stephanie".

Persistent Cerebral 18-FDG PET Changes in Patients With Long COVID Presenting With Fatigue and Post Exertional Malaise
Ganesh, Ravindra , Nair, Kaavya, Grach, Stephanie L. , Croghan, Ivana T. , Yadav, Siddhant, Mueller, Michael , Hurt, Ryan T. , Mueller, Michael R , Ganesh, Ravindra , Grach, Stephanie L , Nair, Kaavya

Mayo Clinic

Journal of Primary Care & Community Health | June 9, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261458748 | PMID 42259512 Get It

Objective Long COVID (LC) refers to the long-term symptoms occurring after SARS-CoV-2 infection and resolution of the initial disease prodrome. While LC is increasingly recognized, knowledge about its biomarkers is still limited. This study examines imaging findings in 18 F-FDG PET-CT scans in 40 patients with LC from an academic LC Clinic, for potential imaging biomarkers. Methods This study included patients aged 18 and older with confirmed positive SARS-CoV-2 PCR test and at least 28 days post-symptom onset. 18 F-FDG PET-CT scans were performed, and brain metabolic activity was compared to a control database to generate Z-scores. Participants were grouped based on their clinical phenotype and Z-scores of different brain regions were analyzed using t-tests. Results The study group was mainly female (70%), with a median age of 53 years, and predominantly non-Hispanic White (90%). Most had pre-existing conditions such as gastrointestinal, cardiovascular, endocrine, and psychiatric disorders. The findings showed significant cerebral hypometabolism in 29 patients with fatigue and post-exertional malaise (PEM), particularly in the left sensorimotor cortex (p=0.0253) and bilateral primary visual cortex (right: p=0.0096, left: p=0.0016), which persisted up to two years after infection. Conclusions In summary, this study identified persistent cerebral hypometabolism in LC patients, especially those with fatigue with PEM, up to two years post-infection. These results suggest that 18 F-FDG PET-CT could be a valuable tool for diagnosing and managing LC. Further research is essential to confirm these findings and improve treatment strategies for patients with LC.
Online Menopause Information–Seeking Search Patterns and Commercial Content Over 2 Decades
Farina, Francesca R., Griffith, James W., Faubion, Stephanie S., Hickey, Martha, Lensen, Sarah, Christmas, Monica, Farina, Francesca R , Faubion, Stephanie S. , Hickey, Martha , Lensen, Sarah F. , Christmas, Monica

Mayo Clinic

JAMA Network Open | June 4, 2026 | Volume: 9 | Issue: 6 | Pages: e2616596

10.1001/jamanetworkopen.2026.16596 | PMID 42241006 Get It

This cohort study evaluates 20-year trends to quantify changes in menopause-related online searches compared with other health domains.
Indocyanine Green Fluorescence for Intraoperative Tumor Identification During Resection of Pediatric and Adolescent Intra-Abdominal Malignancy: A Prospective Multi-Institutional Observational Study
Schermerhorn, Sophia MV, Dasgupta, Roshni, Jenkins, Todd , Kastenberg, Zachary, Piché, Nelson , Roach, Jonathan P. , Rhee, Daniel S. , Tracy, Elisabeth T., Davies, Dafydd A., Boehmer, Chloé, Bondoc, Alexander , Tracy, Elisabeth T. , Polites, Stephanie F. , Tracy, Elisabeth T , Hartman, Stephen J. , Dasgupta, Roshni , Lautz, Timothy B. , Kastenberg, Zachary J. , Malek, Marcus M. , Aldrink, Jennifer H. , Brown, Erin G. , Lal, Dave R. , Kim, Eugene S. , Le, Hau D. , Boehmer, Chloé

Mayo Clinic

Journal of the American College of Surgeons | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002056 | PMID 42233485 Get It

Background: Real-time intraoperative discrimination of malignant tissue during pediatric solid tumor resection is limited, constraining margin optimization; the utility of indocyanine green (ICG) fluorescence in this population remains incompletely defined. Study Design: Prospective, observational, multi-institutional study (2019–2023) of pediatric, adolescent, and young adult patients undergoing resection of intra-abdominal solid malignancies following preoperative ICG administration. The primary endpoint was diagnostic accuracy of ICG fluorescence for tumor-containing specimens; secondary endpoints included association with margin status and surgeon-perceived intraoperative benefit. Results: Forty-three operations in 42 patients yielded 55 specimens, of which 47 (85%) were malignant. Diagnostic performance was highest in hepatic tumors (sensitivity 83%, positive predictive value 83%) and lower in adrenal and heterogeneous tumor types. ICG avidity was not associated with improved negative margin rates (86% vs 75%, p=0.47). Surgeons reported intraoperative benefit in 67% of cases, most commonly improved visualization. No ICG-related adverse events occurred. Conclusions: ICG fluorescence provides reliable tumor identification in hepatic malignancies but does not correlate with margin-negative resection, indicating limited utility for margin guidance. These data support tumor-specific application and further investigation of optimized fluorescence strategies, including dosing, timing, and alternative fluorophores, in pediatric oncologic surgery.
Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact
Lebrun‐Frénay, Christine , Landes-Château, Cassandre , Mondot, Lydiane , Cohen, Mikaël , Popolo, Margherita , Sèze, de , Bourre, Bertrand , Casez, Olivier , Kantarci, Orhun H. , Baillif, Stéphanie, Seze, Jerome De , Durand-Dubief, Françoise , Casez, Olivier , Kantarci, OH , Siva, Aksel , Baillif, Stephanie , Okuda, Darin T , Leocani, Letizia , Lebrun‐Frénay, Christine , Bourre, Bertrand , Cohen, Mikaël , Mondot, Lydiane , Durand‐Dubief, Françoise , Sıva, Aksel , Okuda, Darin T.

Mayo Clinic

Annals of Clinical and Translational Neurology | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70441 | PMID 42227083 Get It

ABSTRACT Objectives We aimed to determine the frequency of subclinical optic nerve (ON) lesions using MRI, optical coherence tomography (OCT), and visual evoked potentials (VEP) in radiologically isolated syndrome (RIS), and to assess their diagnostic and prognostic significance. Methods We conducted a retrospective, multicenter study of 179 RIS individuals followed in clinical practice who met the 2023 RISC criteria. The diagnostic performance of the 2024 McDonald criteria, with and without optic nerve assessment, was evaluated and compared with that of the 2017 criteria. Associations with clinical conversion, comorbidities, and MRI disease activity were analyzed using multivariate models. Results Silent ON lesions appeared in 107/179 (59.8%) individuals, mainly detected by VEP (100/164; 61.0%) and OCT (69/118; 58.5%), with routine MRI identifying 31/166 (18.7%). During follow‐up, 71 (39.7%) had a first clinical event. The presence, laterality, or number of silent ON lesions did not correlate with clinical conversion, event type, or MRI activity. Younger age and the absence of comorbidities associated with other MRI lesions, rather than with ON lesions, were associated with clinical conversion. Including ON in the 2024 McDonald criteria increased sensitivity but decreased specificity, with 17/179 (9.5%) meeting dissemination‐in‐space criteria solely due to ON lesions. Interpretation Subclinical ON lesions are common in RIS and are mainly found by OCT and VEP, not routine MRI. Including ON increases sensitivity but does not predict clinical conversion and may lower specificity. These findings suggest cautious interpretation of ON and support a multimodal assessment approach in RIS.
WeCare intervention to improve breast cancer screening and research preparedness in rural and low-socioeconomic women: study protocol for a community-engaged feasibility trial
Min, Hoon‐Ki , Imsande, Kaylynn G, Vitriago, Anni, Seibel, Maria, Rudder, B. de, Watson, Dave , Beenken, Madison, Larson, Stephanie, Flock, Carolyn, Murphy, Crystal, Puljas, Tracy L, Asiedu, Gladys B. , Odedina, Folakemi T, Lynch, Brian , Haddad, Tufia C. , Min, Hoon-Ki Paul , Pritchett, Joshua C. , Rudder, Bongi, Beenken, Madison J, Larson, Stephanie L., Murphy, Crystal M, Patten, Christi A. , Haddad, Tufia C , Tran, Linh Thuy Khanh , Larson, Stephanie L, Flock, Carolyn R.

Mayo Clinic

BMJ Open | June 1, 2026 | Volume: 16 | Issue: 6 | Pages: e113154

10.1136/bmjopen-2025-113154 | PMID 42225362 Get It

Introduction Women residing in rural areas or belonging to lower socioeconomic status (SES) strata experience disproportionately low rates of breast cancer screening, contributing to delayed diagnoses and poorer prognoses. In addition, their participation in clinical trials remains markedly limited, reducing opportunities to access preventive and screening interventions. Promoting research preparedness among women before disease onset may empower them to make informed decisions regarding their health and willingness to participate in clinical research with fewer emotional and logistical barriers. Methods and analysis This project applies a community-based participatory research approach to develop and refine the WeCARE (Women’s Engagement for Cancer Awareness, Resources and Education) intervention for women aged 50–74 years who have either never undergone breast cancer screening or have not received screening in the past 5 years and who reside in rural areas or belong to low SES groups. The intervention consists of two components. Component 1 is a single-day, in-person community forum that includes (a) an educational seminar led by an oncologist to address breast cancer risk and screening guidelines, (b) survivor storytelling to enhance emotional engagement and cultural resonance and (c) facilitated navigation to breast cancer screening and future research participation. Component 2 involves structured post-forum follow-up through multiple touchpoints (phone calls and mailed boosters) to reinforce knowledge, address barriers and support screening completion and research enrolment. Quantitative data (eg, screening completion, satisfaction and follow-up engagement) will be summarised using descriptive statistics to assess feasibility and reach on 50 participants. Qualitative feedback from participants will undergo thematic analysis to identify barriers, facilitators and perceived cultural relevance. Integrated mixed-method interpretation will inform iterative refinement of the WeCARE intervention and guide design of subsequent larger trials. Ethics and dissemination Approved by the Mayo Clinic Institutional Review Board (IRB #25–008934). All participants will provide informed consent. Procedures ensure confidentiality, cultural sensitivity and participant safety. Data will be stored in REDCap and disseminated through publications, conferences, local town halls and community reports.
Blood-based biomarkers and the current landscape of Alzheimer’s disease diagnosis: ethical considerations and practical guidance
Naini, Savana M. , Mantyh, William G., Waldron, Eric J. , Satin, David J. , Basso, Michael R. , Garland, McKenna, McManimen, Stephanie, Whiteside, Douglas M. , Mantyh, William G. , Whiteside, Douglas , Garland, McKenna M. , McManimen, Stephanie L.

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | May 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.1080/13803395.2026.2681010 | PMID 42218590 Get It

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease
Arlt, Friederike A. , Miske, Ramona , Appeltshauser, Luise , Zinnow, Viktoria , Borowski, Kathrin , Stenzel, Werner, Meisel, Andreas , Ruprecht, Klemens, Endres, Matthias , Blau, Igor, Kirchner, Marieluise , Mertins, Philipp , Sanchez-Sendin, Elisa, Wernick, Stephanie , Pressler, Hannah, Stascheit, Frauke , Linke, Janis, Hümmert, Sophie , Werner, Hauke B., Wibisono, Esravila Ariya , Doppler, Kathrin, Komorowski, Lars , Spiliotis, Elias T, Dubey, Divyanshu, Zeckeridou, Anastasia, Mills, John R, Scharf, Madeleine, Prüss, Harald, Werner, Hauke , Meisel, Andreas , Endres, Matthias , Stascheit, Frauke , Pittock, S J , McKeon, Andrew , Prüss, Harald , Arlt, Friederike Antonia , Stenzel, Werner , Radbruch, Helena , Ruprecht, Klemens, Sánchez-Sendín, Elisa , Preßler, Hannah , Linke, Janis , Doppler, Kathrin , Spiliotis, Elias T. , Dubey, Divyanshu , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Mills, J R , McKeon, Andrew , Prüß, Harald

Mayo Clinic

Brain | May 29, 2026 | Volume: 149 | Issue: 8 | Pages: 2731-2746

10.1093/brain/awag183 | PMID 42252093 Get It

Abstract Severe neuropathies with predominant involvement of motor fibres can resemble lower motor neuron disease (LMND) phenotypes. Given the fatal prognosis of LMND, identifying underlying autoimmune syndromes is crucial to provide treatment options to patients. We investigated a novel autoantibody binding pattern observed on murine teased sciatic nerve fibres. Target antigens were identified using immunoprecipitation combined with mass spectrometry. Target specificity of these autoantibodies was validated in cell-based assays, neutralization assays and knock-out models. A retrospective study cohort consisting of different neuropathies (chronic inflammatory demyelinating polyradiculopathy n = 86, Guillain–Barré syndrome n = 37, multifocal motor neuropathy n = 18, diabetic neuropathy n = 30, other inflammatory neuropathies n = 10), amyotrophic lateral sclerosis (n = 50), multiple sclerosis (n = 50) and healthy controls (n = 50) was negative for septin multimer autoantibodies. Histopathological analysis of skin and the sural nerve including electron microscopy was performed in one seropositive patient, and autoantibody binding was characterized in vitro. Extensive immunotherapy was initiated in one patient, with clinical and serological follow-up over 4 years. Among 3543 total samples tested, three patients (two male, one female)—diagnosed with the LMND variant of amyotrophic lateral sclerosis (aged 65, 72 and 79 years, respectively)—showed a novel and distinct autoantibody binding pattern of indirect immunofluorescence staining on peripheral nerves, targeting Schmidt–Lanterman incisures (SLIs), paranodes and the abaxonal myelin. Target identification and validation revealed septin multimers as autoantibody epitopes. Despite the primarily intracellular location of septins, autoantibody binding was evident in living myelinated dorsal root ganglia, primarily at SLIs (‘incisuropathy’). Septin multimer autoantibodies further initiated complement deposition on fixed and permeabilized cell-based assays. Sural nerve and skin biopsies showed inflammation, myelin and axonal pathology. Extensive immunotherapy in one patient was followed by disease stabilization over 3 years. The other two patients died of rapid disease progression: one of them received no immunotherapy while the other had ineffective treatments with single administrations of intravenous immunoglobulin and rituximab. Our data suggest that septin multimer autoimmunity occurs in severe motor-predominant neuropathies which can clinically resemble a neurodegenerative LMND. Screening for septin multimer autoantibodies should be considered in patients presenting with this phenotype. Follow-up studies need to determine the direct pathogenicity of septin multimer autoantibodies, their potential as a biomarker of an autoimmune syndrome and responses to immunotherapy in larger cohorts.
Prognosis of mediastinal lymph node metastases in pediatric patients with osteosarcoma and lung metastases.
Narasimhan, Avantika, Schoettler, Peter, Allen-Rhoades, Wendy A., Santore, Lee Ann , Narasimhan, Avantika Lakshmi , Allen‐Rhoades, Wendy , Polites, Stephanie F.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e22006 Get It

e22006 Background: Metastasectomy is recommended for select pediatric patients with osteosarcoma with resectable pulmonary parenchymal metastases. It is unclear whether pulmonary metastasectomy confers the same benefit to patients with hilar or mediastinal lymph node metastases (LNM). This study aims to characterize pediatric patients with osteosarcoma with thoracic LNM and their outcomes compared to those with only pulmonary parenchymal metastasis. Methods: This is a retrospective cohort study of patients aged 0-21 with osteosarcoma metastatic to the lung who underwent pulmonary metastasectomy between 2000-2024. Patients were categorized into groups based on the presence or absence of LNM on imaging reviewed by pediatric surgeons and radiologists. Descriptive statistics and Wilcoxon rank sum, chi-square or Fisher’s exact tests evaluated differences between patients with and without LNM. Kaplan-Meier survival curves with log-rank tests evaluated the relationship between the presence of LNM and outcomes. The primary outcome was overall survival (OS) with secondary outcomes of recurrence-free survival (RFS) and disease-free survival (DFS). Results: 39 patients met inclusion criteria for this study, of which 13 (33%) had LNM (Table). Of the 13 patients with LNM, 8 (62%) had a pulmonary metastasectomy after their LNM diagnosis. Patients with LNM had poorer OS after first metastasectomy (log-rank p = .027), DFS after first metastasectomy (p = .018), and RFS after diagnosis (p = .039) than patients with pulmonary parenchymal metastasis without LNM. Patients who underwent metastasectomy after their LNM diagnosis had improved OS after LNM diagnosis than patients who did not undergo metastasectomy (pairwise log-rank test with Bonferroni correction p = .015). Conclusions: Pediatric patients with osteosarcoma metastatic to the lung with LNM had poorer OS, DFS, and RFS compared to patients without LNM. These results confirm the importance of attention to the presence of nodal involvement in patients with pulmonary metastatic osteosarcoma. Despite their poor prognosis, these results suggest a persistent survival benefit to surgical intervention. Total N = 39 No LMN N = 26 LMNN = 13 p Age 13.7 (9.5, 16.1) 13.9 (9.0, 15.9) 13.7 (10.7, 16.5) .777 Female 15 (38%) 10 (38%) 5 (38%) > .999 Histology Chondroblastic Osteoblastic Telangiectatic 11 (39%)16 (57%)1 (3.6%) 9 (50%)8 (44%)1 (5.6%) 2 (20%)8 (80%)0 (0%) .162 Primary tumor site Chest wall Femur Humerus Pelvis Radius Tibia 2 (5.1%)24 (62%)5 (13%)2 (5.1%)1 (2.6%)5 (13%) 2 (7.7%)14 (54%)3 (12%)2 (7.7%)1 (3.8%)4 (15%) 0 (0%)10 (77%)2 (15%)0 (0%)0 (0%)1 (7.7%) .821 Lung metastases present at time of diagnosis 20 (51%) 13 (50%) 7 (54%) .821 Treatment protocol AOST0331 AOST06P1 CCG 7921 P9754 30 (81%)2 (5.4%)4 (11%)1 (2.7%) 19 (79%)1 (4.2%)3 (13%)1 (4.2%) 11 (85%)1 (7.7%)1 (7.7%)0 (0%) > .999 Lung nodules removed during first metastasectomy 3 (2, 6) 3 (2, 5) 6 (1, 20) .567
BCG at home: A first-in-kind pilot trial of home-based intravesical Bacillus Calmette-Guérin delivery for high-risk non-muscle-invasive bladder cancer.
Lee, D C, Fidyk, Danielle, Kessler, Stephanie, Northern, Lindsay, Radovanovich, Alexander, Kim, David, Cappozzi, Donna, Obare, Aquilla, Stambakio, Hanna, Wang, Shirley , Guzzo, Thomas, Bivalacqua, Trinity, Soefje, Scott A. , Guzzo, Thomas J., Bivalacqua, Trinity J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e13615 Get It

e13615 Background: Bacillus Calmette-Guérin (BCG) remains the standard intravesical therapy for high-risk non-muscle-invasive bladder cancer (NMIBC), but weekly clinic-based instillations create substantial travel, time, and indirect costs that may threaten adherence. Therefore, we proposed a pilot trial of delivering BCG at Home as a prospective, single-center pilot testing a pharmacy-to-home pathway with digital patient-reported outcome (PRO) monitoring. Methods: BCG at Home is a prospective, single-center pilot evaluating feasibility and safety of home delivery of induction BCG for treatment-naïve, high-grade T1 and/or carcinoma in situ NMIBC. Dose 1 is administered in clinic to confirm tolerability and catheterization feasibility; doses 2-6 are administered at home by Penn Medicine at Home nurses after a 3 month training and proctorship program in intravesical therapy and exposure precautions. To enable transport beyond conventional short post-preparation windows, the pharmacy prepares BCG using a closed system transfer device (CSTD); bench testing demonstrated stability and sterility for 24 hours after connection. A medical courier delivers the prepared medication to the patient’s home, where the nurse receives the delivery and performs the instillation. The primary endpoint is induction adherence (completion of all recommended doses). Secondary endpoints include PROs (EORTC QLQ-C30/QLQ-NMIBC24), satisfaction, and acute care utilization. PROs are captured before and after treatment using a conversational chatbot; domain summaries are assessed at baseline, 6 weeks, and 12 weeks. Results: The pilot began enrollment in June 2025 (planned sample size: 20). To date, eight participants have enrolled and completed induction. Median age was 76 years (range 41-88); 50% were female and 25% were Black/African American. Participants lived a mean of 30 miles from the treating facility. Forty home instillations were delivered, and all participants completed all recommended induction doses (100% adherence). Median nurse time in the home was 40 minutes. Five episodes of hematuria were self-limited; one urinary tract infection resolved with antibiotics. Self-efficacy improved from a median of 3 pre-treatment to 7 post-treatment. The median COST-FACIT score was 30 (scale 1-44). Mean EORTC QLQ-C30 global health status was 71 (0-100). EORTC QLQ-NMIBC24 averages showed urinary symptoms rising during induction (23 at baseline to 30 at 6 weeks) with improvement by 12 weeks (18) and future worries decreasing (33 to 25); intravesical treatment issues remained low (5 to 2). Conclusions: BCG at Home is, to our knowledge, the first prospective trial to administer intravesical BCG in the home setting using a standardized pharmacy-to-home pathway. Early results support feasibility, complete adherence, and an acceptable short-term safety profile. Clinical trial information: 07048496 .
cfDNA WGS vs plasma proteomics for minimally invasive MRD assessment in multiple myeloma.
Abelman, Dor, Wong, Aimee, Eagles, Jenna , Shah, Saumil , Bruce, Jeff, Campos, Cecília Bonolo de , White, Darrell, Song, Kevin , Braggio, Esteban, Murugesan, Alli , Stewart, Keith, Reiman, Tony, Trudel, Suzanne, Abelman, Dor , Wong, Aimee, Bruce, Jeffrey, Pedersen, Stephanie , Scott, David S. , Chow, Signy , White, Darrell , Sandhu, Irwindeep , Braggio, Esteban , Trudel, Suzanne , Pugh, Trevor J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7546-7546

10.1200/jco.2026.44.16_suppl.7546 Get It

7546 Background: MRD assessment informs relapse risk in MM but is typically bone marrow-based and invasive. We therefore compared two minimally invasive MRD assays: BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM). Methods: 71 longitudinal plasma samples (22 diagnosis, 49 follow-up) from 22 newly diagnosed MM patients across 8 Canadian sites (TFRIM4) had paired cfWGS and EasyM (Rapid Novor Inc). cfWGS MRD used patient-specific mutation lists from diagnostic BM WGS (Abelman et al., medRxiv 2025). EasyM used mass spectrometry to quantify residual M-protein from baseline. The primary endpoint was progression-free survival (PFS). Results: Among 22 MM patients (8 male, 14 female; median age at diagnosis 62 years), 8 progressed at a median follow-up of 52.6 months (range: 10-79 months). At 1-year maintenance (n = 18 available), cfWGS MRD+ (6/18) predicted inferior PFS (HR 20.12, 95% CI 2.23-181.60, p = 0.007). EasyM any-detect positivity was frequent (16/18, reflecting delayed clearance) and not prognostic (p = 0.99), with poor agreement vs cfWGS (44.4%, κ = 0.118). An exploratory EasyM clearance threshold of 0.93% (hypothesis-generating) classified 5/18 patients as MRD+ and stratified PFS (HR 8.78, 95% CI 1.55-49.82, p = 0.004), improving agreement with cfWGS (17/18, 94.4%, κ = 0.870). Progression clustered in cfWGS+/EasyM-high patients (EasyM >0.93%; 4/5; median 11.9 months post-collection [1.9–22.8]) and occurred once in cfWGS−/EasyM-low patients (1/12, 27.6 months). The only discordant case (cfWGS+/EasyM−) progressed 8.7 months after collection. Higher quantitative MRD burden was associated with inferior PFS (cfWGS: HR 2.92 per 1 SD, 95% CI 1.29-6.59, p = 0.01; EasyM: HR 5.48 per 1 SD, 95% CI 0.79-37.90, p = 0.085). At ~100 days post-autologous stem cell transplantation (ASCT; n = 16 available), EasyM was uniformly MRD+ (16/16) while cfWGS was MRD+ in 7/16 patients. Applying an EasyM clearance threshold (2.13%; 9 cleared vs 7 residual) improved agreement with cfWGS (14/16; 87.5%; κ = 0.746). Of two discordant cases, one cfWGS+/EasyM-cleared patient relapsed 38.6 months post-collection and one cfWGS−/EasyM-residual patient remained progression-free at last follow-up. At post-ASCT, both assays showed consistent but underpowered associations with PFS (cfWGS HR 6.32, 95% CI 0.70–56.76, p = 0.100; EasyM-clearance HR 2.36, 95% CI 0.39–14.18, p = 0.335). Across all post-treatment samples (n = 49), continuous cfWGS burden correlated with EasyM residual M-protein (rho = 0.535, p < 0.001). Conclusions: BM-informed cfWGS MRD strongly stratified PFS, whereas EasyM required a clearance definition due to near-universal early positivity. Concordant plasma burdens support complementary MRD information. Future work will validate these findings in larger cohorts and quantify the incremental value of combined cfWGS and proteomic MRD for early relapse prediction.